Protagonist Therapeutics
Newark, CA
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary peptide NCE platform and two drugs in late-stage FDA review. Their pipeline targets inflammation, hematology, and metabolic disease using novel oral and injectable peptide therapeutics.
Services Offered
- Clinical-stage peptide drug development
- Oral peptide NCE research
- Inflammation and metabolic disease research
- Hematology drug development
About
Protagonist Therapeutics has built one of the most advanced clinical-stage peptide pipelines in the US, with two drugs — icotrokinra (an oral IL-23 receptor antagonist for inflammatory disease) and rusfertide (a hepcidin mimetic for hematologic conditions) — each with NDAs filed with the FDA. Their proprietary platform enables the design of orally bioavailable peptide therapeutics, historically a major challenge in drug development.
Peptide Specialties
Contact
Disclaimer: Listings are for informational purposes. Informed Peptide does not endorse, recommend, or verify the medical services of listed providers. Always consult a licensed healthcare professional.